Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained
How Novo Nordisk's Board Built a Weight-Loss Empire
In this episode of Boardroom Conversations, Lucas and Luna dive into the strategic decisions behind Novo Nordisk's meteoric rise as the world's dominant weight-loss drug maker. They explore how the board greenlit massive manufacturing investments years before Wegovy and Ozempic were approved for obesity, how they navigated supply shortages and competition, and why the company's market value now exceeds Denmark's entire GDP. A masterclass in long-term board-level betting on a scientific thesis.
#NovoNordisk #Wegovy #Ozempic #WeightLossDrugs #Pharma #BoardStrategy…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.